Navigation Links
Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Alteon Inc. announced today that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications.

This dose escalating study is designed to evaluate ALT-2074's ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events.

It builds on positive data from previous cardiovascular animal studies. ALT- 2074's activity in prior clinical trials demonstrated its safety and ability to lower inflammatory markers in ulcerative colitis.

'The initiation of Study 201 is a key milestone in our program for the development of ALT-2074 as a treatment for diabetic patients with a high risk of cardiovascular events,'said Malcolm W. MacNab, M.D., Ph.D., Alteon's Vice President, Clinical Development.

'We are enthusiastic about the potential that ALT-2074 has demonstrated in our preclinical models and we are aggressively pursuing clinical development in this indication.'

Diabetes and Metabolic Syndrome, diseases linked to obesity and increased oxidative stress, are growing in epidemic proportions in the United States and many other developed countries.

The major complications associated with these diseases are cardiovascular in nature, and lead to such events as stroke, heart attack, kidney failure and death. Not all patients with diabetes, however, experience these complications.

Several multinational studies have demonstrated that the increased risk of cardiovascular disease attributed to diabetes is more aptly attributed to the development of diabetes 'on top of' a predisposing genetic factor called Haptoglobin 2-2 (Hp2-2), which is found in 40% of the human population.

The combination of diabetes and Hp2-2 increases the susceptibil ity of patients to a defect in their cholesterol metabolism, which may promote atherosclerosis, and to a weakness in their antioxidant defense, so essential to the human body when oxygen is less available (during a heart attack for example).

Targeting a potent antioxidant drug candidate like ALT-2074 to these high risk patients is an example of targeted therapy. By redefining diabetes, Alteon believes that it can advance an efficient clinical development program in which a more appropriately targeted therapy is given to a more susceptible patient population.




'"/>




Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: